Antiangiogenic therapy for high-grade gliomas: current concepts and limitations

References

• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8(8), 610–622 (2007).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3), 353–364 (1996).
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Kuczynski EA, Patten SG, Coomber BL. VEGFR2 expression and TGF-beta signaling in initial and recurrent high-grade human glioma. Oncology 81(2), 126–134 (2011).
   PubMed Web of Science ®Google Scholar
• Xu C, Wu X, Zhu J. VEGF promotes proliferation of human glioblastoma multiforme stem-like cells through VEGF receptor 2. ScientificWorldJournal 2013, 417413 (2013).
   Google Scholar
• Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematol. Oncol. Clin. North Am. 18(5), 1007–1021, viii (2004).
   PubMed Web of Science ®Google Scholar
• Mayer A, Schneider F, Vaupel P, Sommer C, Schmidberger H. Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma. Int. J. Oncol. 41(4), 1260–1270 (2012).
   PubMed Web of Science ®Google Scholar
• Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ. Res. 81(4), 567–574 (1997).
   PubMed Web of Science ®Google Scholar
• Chi AS, Norden AD, Wen PY. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics 6(3), 513–526 (2009).
   PubMed Web of Science ®Google Scholar
• Chinot OL, de La Motte Rouge T, Moore N et al. AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv. Ther. 28(4), 334–340 (2011).
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam J, Won M et al. RTOG 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 31(Suppl.), Abstract 1 (2013).
   Google Scholar
• Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733–4740 (2009).
   PubMed Web of Science ®Google Scholar
• Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin. Cancer Res. 15(14), 4589–4599 (2009).
   PubMed Web of Science ®Google Scholar
• Taal W, Oosterkamp HM, Walenkamp AME et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch BELOB study. J. Clin. Oncol. 31(Suppl. Abstract 2001) (2013).
   Google Scholar
• Rahman R, Smith S, Rahman C, Grundy R. Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. J. Oncol. 2010, 251231 (2010).
   PubMedGoogle Scholar
• von Baumgarten L, Brucker D, Tirniceru A et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin. Cancer Res. 17(19), 6192–6205 (2011).
   PubMed Web of Science ®Google Scholar
• de Groot JF, Lamborn KR, Chang SM et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J. Clin. Oncol. 29(19), 2689–2695 (2011).
   PubMed Web of Science ®Google Scholar
• Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11(7), 753–764 (2006).
   PubMed Web of Science ®Google Scholar
• de Bouard S, Herlin P, Christensen JG et al. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro. Oncol. 9(4), 412–423 (2007).
   PubMed Web of Science ®Google Scholar
• Pan E, Yu D, Yue B et al. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J. Neurooncol. 110(1), 111–118 (2012).
   PubMed Web of Science ®Google Scholar
• Nabors LB, Supko JG, Rosenfeld M et al. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro. Oncol. 13(12), 1324–1330 (2011).
   PubMed Web of Science ®Google Scholar
• Siegelin MD, Raskett CM, Gilbert CA, Ross AH, Altieri DC. Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci Lett, 478(3), 165–170 (2010).
   PubMed Web of Science ®Google Scholar
• Lee EQ, Kuhn J, Lamborn KR et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro. Oncol. 14(12), 1511–1518 (2012).
   PubMed Web of Science ®Google Scholar
• Conrad C, Friedman H, Reardon D et al. A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). J. Clin. Oncol. (Meeting Abstracts) 22(14 Suppl.) 1512 (2004).
   Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1), 83–95 (2007).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Mulholland P, Neyns B et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J. Clin. Oncol. 31(26), 3212–3218 (2013).
   PubMed Web of Science ®Google Scholar
• Marx GM, Pavlakis N, McCowatt S et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J. Neurooncol. 54(1), 31–38 (2001).
   PubMed Web of Science ®Google Scholar
• Fine HA, Kim L, Albert PS et al. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin. Cancer Res. 13(23), 7101–7106 (2007).
   PubMed Web of Science ®Google Scholar
• Drappatz J, Wong ET, Schiff D et al. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 73(1), 222–227 (2009).
   PubMed Web of Science ®Google Scholar
• Raymond E, Brandes AA, Dittrich C et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J. Clin. Oncol. 26(28), 4659–4665 (2008).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Quinn JA, Vredenburgh J et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103(2), 329–338 (2005).
   PubMed Web of Science ®Google Scholar
• Tuettenberg J, Grobholz R, Korn T, Wenz F, Erber R, Vajkoczy P. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J. Cancer Res. Clin. Oncol. 131(1), 31–40 (2005).
   PubMed Web of Science ®Google Scholar
• Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 59(6), 1304–1312, discussion 1312 (2006).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Fink KL, Mikkelsen T et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26(34), 5610–5617 (2008).
   PubMed Web of Science ®Google Scholar
• Kamoun WS, Ley CD, Farrar CT et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol. 27(15), 2542–2552 (2009).
   PubMed Web of Science ®Google Scholar
• Mangiola A, Anile C, Pompucci A, Capone G, Rigante L, De Bonis P. Glioblastoma therapy: going beyond Hercules columns. Expert Rev. Neurother. 10(4), 507–514 (2010).
   PubMed Web of Science ®Google Scholar
• Mangiola A, de Bonis P, Maira G et al. Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme. Cancer 113(4), 841–846 (2008).
   PubMed Web of Science ®Google Scholar
• Mangiola A, Saulnier N, De Bonis P et al. Gene expression profile of glioblastoma peritumoral tissue: an ex vivo study. PLoS ONE 8(3), e57145 (2013).
   PubMed Web of Science ®Google Scholar
• Sica G, Lama G, Anile C et al. Assessment of angiogenesis by CD105 and nestin expression in peritumor tissue of glioblastoma. Int. J. Oncol. 38(1), 41–49 (2011).
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin. Cancer Res. 14(20), 6371–6375 (2008).
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8(8), 592–603 (2008).
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3), 232–239 (2009).
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3), 220–231 (2009).
   PubMed Web of Science ®Google Scholar
• Lu KV, Chang JP, Parachoniak CA et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22(1), 21–35 (2012).
   PubMed Web of Science ®Google Scholar
• De Bonis P, Anile C, Pompucci A et al. The influence of surgery on recurrence pattern of glioblastoma. Clin. Neurol. Neurosurg. 115(1), 37–43 (2013).
   PubMed Web of Science ®Google Scholar
• Binda E, Visioli A, Giani F et al. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 22(6), 765–780 (2012).
   PubMed Web of Science ®Google Scholar